» Articles » PMID: 24648610

Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans

Overview
Journal Dis Markers
Publisher Wiley
Specialty Biochemistry
Date 2014 Mar 21
PMID 24648610
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Changes of glycosylation pattern in serum proteins have been linked to various diseases including cancer, suggesting possible development of novel biomarkers based on the glycomic analysis. In this study, N-linked glycans from human serum were quantitatively profiled by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and compared between healthy controls and ovarian cancer patients. A training set consisting of 40 healthy controls and 40 ovarian cancer cases demonstrated an inverse correlation between P value of ANOVA and area under the curve (AUC) of each candidate biomarker peak from MALDI-TOF MS, providing standards for the classification. A multibiomarker panel composed of 15 MALDI-TOF MS peaks resulted in AUC of 0.89, 80~90% sensitivity, and 70~83% specificity in the training set. The performance of the biomarker panel was validated in a separate blind test set composed of 23 healthy controls and 37 ovarian cancer patients, leading to 81~84% sensitivity and 83% specificity with cut-off values determined by the training set. Sensitivity of CA-125, the most widely used ovarian cancer marker, was 74% in the training set and 78% in the test set, respectively. These results indicate that MALDI-TOF MS-mediated serum N-glycan analysis could provide critical information for the screening of ovarian cancer.

Citing Articles

Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer.

Blaschke C, Hill E, Mehta A, Angel P, Laronga C, Drake R Sci Rep. 2022; 12(1):20801.

PMID: 36460712 PMC: 9718781. DOI: 10.1038/s41598-022-25401-0.


Determination of monosaccharide composition in human serum by an improved HPLC method and its application as candidate biomarkers for endometrial cancer.

Chen Y, Yao Q, Zeng X, Hao C, Li X, Zhang L Front Oncol. 2022; 12:1014159.

PMID: 36408150 PMC: 9671074. DOI: 10.3389/fonc.2022.1014159.


Toward improvement of screening through mass spectrometry-based proteomics: ovarian cancer as a case study.

Luu G, Sanchez L Int J Mass Spectrom. 2021; 469.

PMID: 34744497 PMC: 8570641. DOI: 10.1016/j.ijms.2021.116679.


Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges.

Wanyama F, Blanchard V Diagnostics (Basel). 2021; 11(4).

PMID: 33916250 PMC: 8065431. DOI: 10.3390/diagnostics11040643.


Potential of MALDI-TOF-based serum N-glycan analysis for the diagnosis and surveillance of breast cancer.

Lee J, Lee K, Ahn S, Son B, Ko B, Kim H Sci Rep. 2020; 10(1):19136.

PMID: 33154535 PMC: 7644762. DOI: 10.1038/s41598-020-76195-y.


References
1.
Elder J, Alexander S . endo-beta-N-acetylglucosaminidase F: endoglycosidase from Flavobacterium meningosepticum that cleaves both high-mannose and complex glycoproteins. Proc Natl Acad Sci U S A. 1982; 79(15):4540-4. PMC: 346710. DOI: 10.1073/pnas.79.15.4540. View

2.
Kronewitter S, An H, de Leoz M, Lebrilla C, Miyamoto S, Leiserowitz G . The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics. 2009; 9(11):2986-94. PMC: 2758495. DOI: 10.1002/pmic.200800760. View

3.
Kirmiz C, Li B, An H, Clowers B, Chew H, Lam K . A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 2006; 6(1):43-55. DOI: 10.1074/mcp.M600171-MCP200. View

4.
Bast Jr R, Xu F, Yu Y, Barnhill S, Zhang Z, Mills G . CA 125: the past and the future. Int J Biol Markers. 1999; 13(4):179-87. DOI: 10.1177/172460089801300402. View

5.
Zurawski Jr V, Orjaseter H, Andersen A, Jellum E . Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988; 42(5):677-80. DOI: 10.1002/ijc.2910420507. View